Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
- 86 Downloads
Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified.
MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m2 of irinotecan, at six institutions were retrospectively analyzed.
A total of 43 patients were assessed. Median age was 63 years, and 22 patients (51%) were women. Twenty-six patients (60%) were given ramucirumab plus FOLFIRI as second-line therapy, and 17 (40%) as third or later-line. The median relative dose intensity (RDI) of irinotecan was 60.6%, which is lower than that in the pivotal phase 3 study (RAISE), and other agents showed the same trend. Median progression-free survival was 4.8 [95% confidence interval (CI) 3.2–5.7] months for all patients, 5.4 (95% CI 3.5–7.2) months for second-line patients, and 2.8 (95% CI 1.6–5.8) months for third or later-line patients. Median overall survival was 17.3 (95% CI 11.5–22.4) months for all patients. Patients with irinotecan RDI less than 60% showed similar treatment efficacy. Hematological toxicities of grade 3 or worse were observed in 21 patients, but all were manageable.
Low RDI did not compromise the treatment efficacy of ramucirumab plus modified FOLFIRI for MCRC patients.
KeywordsColorectal cancer Ramucirumab Irinotecan Relative dose intensity
The authors would like to thank all the participating patients and medical staff who treated the patients in each institution.
Compliance with ethical standards
Conflict of interest
Akitaka Makiyama have received a speaker honorarium from Eli Lilly. Taito Esaki has received a speaker honorarium from Daiichi Sankyo and Eli Lilly and has received research grants from Daiichi Sankyo. Koichi Akashi has received speaker honorarium from Kyowa Hakko Kirin. Koichi Akashi has received research grants from Kyowa Hakko Kirin, Yakult, Eli Lilly and Daiichi Sankyo. Eishi Baba has received a speaker honorarium and research grants from Eli Lilly. The other authors have no conflict of interest.
- 1.WHO cancer today (2018) http://gco.iarc.fr/today/online-analysis-multi-bars?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=1&statistic=0&prevalence=0&color_palette=default. Accessed 29 Oct 2018
- 5.Department of Health and Human Services Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research (2014) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125477Orig1s000PharmR.pdf. Accessed 29 Oct 2018
- 6.Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508CrossRefGoogle Scholar
- 8.Cancer Therapy Evaluation Program, National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE) v4.0Google Scholar
- 10.Grothey A, Yoshino T, Bodoky G et al (2018) Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open 3(3):e000347CrossRefGoogle Scholar
- 13.Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506CrossRefGoogle Scholar
- 15.Wirapati P, Pomella V, Vandenbosch B et al (2017) VELOUR trial biomarkers update: impact of RAS, BRAF, and sidedness on aflibercept activity. Ann Oncol 1(suppl_3):28Google Scholar
- 22.Yoshino T, Yamazaki K, Gotoh M et al (2015) Safety and pharmacokinetics of second-line ramucirumab plus FOLFIRI in Japanese Patients with metastatic colorectal carcinoma. Anticancer Res 35:4003–4007Google Scholar
- 23.Komiyama S, Kato K, Inokuchi Y et al (2018) Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol. https://doi.org/10.1007/s10147-018-1319-y Google Scholar